Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with sintilimab and lenvatinib for advanced unresectable hepatocellular carcinoma
ChiCTR2200057478Phase 2Not yet recruiting
- Sponsor
- Huizhou Central People's Hospital
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, lenvatinib, oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC), sponsored by Huizhou Central People's Hospital. Primary endpoint: Objective response rate assessed by RECIST 1.1. Planned start May 2022; status: not yet recruiting.
02
Drugs
sintilimablenvatiniboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200057478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057478.